Vimarsana
Biggest News Aggregation in the World

Page 2 - Registry Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Registry Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Registry Study Today - Breaking & Trending Today

GT Medical Technologies Marks a Clinical Milestone: 200th Patient Enrolled in the Multicenter Observational Registry of GammaTile® Therapy - Vimarsana News

GT Medical Technologies Marks a Clinical Milestone: 200th Patient Enrolled in the Multicenter Observational Registry of GammaTile® Therapy

/PRNewswire/ -- GT Medical Technologies, Inc., a medical technology company dedicated to improving the lives of patients with brain tumors, announced its 200th...

Vifor International AG (CSL Vifor): Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus - Vimarsana News

Vifor International AG (CSL Vifor): Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus - Vimarsana News

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease -associated pruritus in adult... | June 11, 2023

Sons of women with PCOS 3 times more likely to develop obesity - Vimarsana News

Sons of women with PCOS 3 times more likely to develop obesity

The study from Karolinska Institutet, Sweden, said that it highlighted a previously unknown risk of passing PCOS-related health problems across generations through the male side of a family

CSL Vifor: Kapruvia approved in Switzerland with additional regulatory decisions expected in H2 2022 - Vimarsana News

CSL Vifor: Kapruvia approved in Switzerland with additional regulatory decisions expected in H2 2022

Kapruvia (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients Therapy recently